Aziyo Biologics Inc, a commercial-stage regenerative medicine company, has filed Amendment No 1 to Form S-1 Registration Statement on September 30, 2020 with the U.S. Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $50 million by offering 2.9 million shares at the price range of $16 to $18. Assuming a successful IPO at the midpoint of the proposed range, the company expects a market capitalization of $177 million.
The company has developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material. Its proprietary products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction.
The Silver Spring, Maryland-based company was founded in 2015 and booked $42 million in revenue for the 12 months ended June 30, 2020. It plans to list on the Nasdaq Global Market under the symbol “AZYO.” Piper Sandler, Cowen, Cantor Fitzgerald and Truist Securities are underwriters of the IPO.
The company engages Latham & Watkins LLP as US Securities Counsel, and PricewaterhouseCoopers LLP as Independent Auditor.
#ipo #nasdaq #Pw C #aziyo #biological #regenerative #natural #medicine
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
